GFM
ADMA icon

GF Fund Management’s ADMA Biologics ADMA Stock Holding History

GF Fund Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.2K Sell
5,041
-305
-6% -$2.78K ﹤0.01% 406
2026
Q1 		$48.2K Buy
5,346
+670
+14% +$10.6K ﹤0.01% 403
2025
Q4 		$85.3K Sell
4,676
-458
-9% -$7.72K ﹤0.01% 362
2025
Q3 		$75.3K Sell
5,134
-919
-15% -$15.8K ﹤0.01% 357
2025
Q2 		$110K Hold
6,053
– – ﹤0.01% 357
2025
Q1 		$120K Buy
6,053
+1,089
+22% +$18.8K ﹤0.01% 352
2024
Q4 		$85.1K Buy
+4,964
New +$93.4K ﹤0.01% 339

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GF Fund Management's ADMA Position: Q2 2026 in Review

GF Fund Management reduced its ADMA Biologics (ADMA) stake by 5.7% in Q2 2026, selling an estimated $2.78K and leaving 5,041 shares worth $42.2K. The position accounts for ﹤0.01% of the portfolio, ranked #406.

GF Fund Management first reported a position in ADMA in Q4 2024 and has held it in 7 quarters since. The position peaked at $120K in Q1 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • GF Fund Management held 5,041 shares of ADMA Biologics worth $42.2K as of Q2 2026.
  • GF Fund Management sold 305 ADMA Biologics shares in Q2 2026, an estimated $2.78K.
  • ADMA Biologics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #406 holding.
  • GF Fund Management first reported a position in ADMA Biologics in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's ADMA Biologics position peaked at $120K in Q1 2025.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.